RAF1 and thyroid cancer: Similar to Sorafenib, these compounds inhibit KDR function and it is of interest that the effects in vivo did not correlate with inhibition of RAF activity for one of the cell lines, further suggesting that several targets may be therapeutically important in progressive thyroid cancer.